Thu. 7 Mar 2024, 4:23pm ET
Benzinga
Earnings, Earnings Beats, Earnings Misses, News
Oncternal Therapeutics (NASDAQ:ONCT) reported quarterly losses of $(3.110) per share which missed the analyst consensus estimate of $(3.070) by 1.3 percent. This is a 22.83 percent increase over losses of $(4.030) per share from the same period last year. The company reported quarterly sales of $297.000 thousand which beat the analyst consensus estimate of $137.500 thousand by 116.00 percent. This is a 73.68 percent increase over sales of $171.000 thousand the same period last year.